Clinical efficacy and safety of injection of lobaplatin via hepatic artery puncture combined with percutaneous portal venipuncture in the treatment of middle and late primary liver cancer
10.3760/cma.j.issn.1008-6706.2019.16.013
- VernacularTitle: 注射用洛铂经肝动脉穿刺联合经皮门静脉穿刺治疗中晚期原发性肝癌的临床疗效及安全性分析
- Author:
Lidong GAO
1
;
Xiumei WANG
2
;
Jianliang WU
3
Author Information
1. Department of Pharmacy Intravenous Admixture Services, Binzhou Central Hospital(Binzhou Tuberculosis Prevention and Treatment Hospital), Binzhou, Shandong 251700, China
2. Department of CT Room, Binzhou Central Hospital(Binzhou Tuberculosis Prevention and Treatment Hospital, Binzhou Tumor Hospital), Binzhou, Shandong 251700, China
3. Department of Medical Oncology, Binzhou Central Hospital(Binzhou Tuberculosis Prevention and Treatment Hospital, Binzhou Tumor Hospital), Binzhou, Shandong 251700, China
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Percutaneous catheter selective portal vein embolism;
Hyperselective hepatic artery chemoembolization;
Los platinum;
Medicated embolism;
Regional embolization of liver cancer;
Clinical efficacy;
Security
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(16):1970-1976
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy and safety of injecting lobaplatin through hepatic artery puncture combined with percutaneous catheter selective portal vein embolization(SPVCE) in the treatment of primary liver cancer.
Methods:A total of 118 patients with advanced primary liver cancer admitted to Binzhou Central Hospital of Shandong Province from August 2015 to January 2017 were selected as in the study, and randomly divided into two groups according to the digital table, namely TACE(hepatic carcinoma arterial perfusion chemoembolization)+ SPVCE group and TACE group, with 59 cases in each group.In the TACE+ SPVCE group, injection lobaplatin was administered with gelatin sponge as the drug-borne embolic agent, superselective hepatic artery chemoembolization(TACE) combined with SPVCE was performed, regional embolization was performed for liver cancer, and only TACE was administered in the TACE group.The curative effect and adverse reactions of the two groups were observed and compared.
Results:The short-term objective(CR+ PR) efficiency of the TACE+ SPVCE group was 74.57%(44/59), which was significantly higher than that of the TACE group [54.23% (32/59)], the difference was statistically significant(χ2=5.323, P=0.021). The differences were statistically significant in the main indicators, such as the decrease of tumor lesion volume, the increase of liver volume without cancer, and the decrease of FAP(all P<0.05). The long-term objective efficiency of the TACE+ SPVCE group was 45.76%(27/59), which was also significantly higher than that of the TACE group[32.2%(19/59)], but the difference was no statistically significant(χ2=2.280, P=0.131). The TACE+ SPVCE group extended the median survival time by 3.5 months compared to the TACE group, there was statistically significant difference in median survival between the two groups(t=3.211, P=0.000). Major adverse reactions were compared between the two groups, the patients with decreased albumin in the TACE + SPVCE group was less than the TACE group, but there was no statistically significant difference(χ2=1.156, P=0.282), the patients with bone marrow inhibition in the TACE + SPVCE group decreased significantly compared with the TACE group, the difference was statistically significant(χ2=4.882, P=0.027), patients with severe gastrointestinal tract decreased compared with conventional TACE group, but there was no statistically significant difference(χ2=1.035, P=0.308).
Conclusion:Injection for drug carrier with lobaplatin with gelatin sponge embolism agent, percutaneous puncture catheter super choice hepatic artery hepatic artery embolism chemotherapy combined with percutaneous puncture catheter SPVCE for primary liver cancer lines of regional embolization, is safe and effective, and can improve the curative effect of conventional TACE, and prolong survival, has important clinical value for advanced liver cancer patients that cannot be surgically removed.
